Cover Image

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION

Show other versions (1)

<p>Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance in percutaneous coronary intervention (PCI), to identify clinical risk factors of resistance development, to study effects of concomitant therapy on resistance development, to identify relationsh...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. A. Sulimov (Author), E. V. Moroz (Author)
Format:	Book
Published:	Столичная издательская компания, 2015-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
by: V. A. Sulimov, et al.
Published: (2015)

Mapping the antiplatelet effects of clopidogrel and aspirin by modified thromboelastography
by: Hemlata, et al.
Published: (2013)

Effect of Calcium Channel Blockers on Antiplatelet Activity of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PTRG-DES Consortium
by: HoungBeom Ahn MD, et al.
Published: (2024)

Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention
by: Bin YANG, et al.
Published: (2018)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015)

The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019)

Association of ABCC2 polymorphism with clopidogrel response in Chinese patients undergoing percutaneous coronary intervention
by: Lida Chen, et al.
Published: (2022)

IS THE SYNTAX SCORE SUFFICIENT TO ASSESS THE RISK FOR PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTIONS?
by: E. S. Novikova, et al.
Published: (2017)

ANTITHROMBOTIC THERAPY AT PERCUTANEOUS CORONARY INTERVENTIONS
by: V. A. Sulimov
Published: (2016)

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015)

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015)

ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION
by: D. H. Ainetdinova, et al.
Published: (2016)

Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry - Informing optimal antiplatelet strategies
by: Larisa H. Cavallari, et al.
Published: (2024)

Current views on antiplatelet therapy in acute coronary syndrome patients: the place of clopidogrel
by: O. O. Shakhmatova
Published: (2022)

Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020)

Efficacy and safety of concomitant use of proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: A systematic review and meta-analysis
by: Xiaofeng Luo, et al.
Published: (2023)

Bleeding events occurring in patients sdminitering double antiplatelet therapy (aspirin + P2Y12 inhibitor - clopidogrel)
by: Marta DOGOT, et al.
Published: (2023)

THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS
by: O. V. Gaisenok
Published: (2016)

THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS
by: O. V. Gaisenok
Published: (2016)

Molecular genomic and epigenomic characteristics related to aspirin and clopidogrel resistance
by: Jei Kim, et al.
Published: (2024)

Impact of CYP2C19 variants on clinical efficacy of clopidogrel and one-year clinical outcomes in coronary heart patients undergoing percutaneous coronary intervention
by: Hong Sun, et al.
Published: (2016)

Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
by: Jialun Han, et al.
Published: (2023)

From Coronaries to Cirrhosis: The Role of Percutaneous Coronary Intervention and Dual Antiplatelet Therapy in End-Stage Liver Disease
by: Taylor C. Remillard MD, et al.
Published: (2021)

In silico Investigation on Clopidogrel, Prasugrel and Ticagrelor as Potential Mono Antiplatelet Therapy for Acute Coronary Syndrome
by: Muhammad Naufal Hibatullah, et al.
Published: (2024)

Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome
by: Son V Pham, et al.
Published: (2010)

Digital Tool-Assisted Hospitalization Detection in the Tailored Antiplatelet Initiation to Lessen Outcomes due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention Study Compared to Traditional Site-Coordinator Ascertainment: Intervention Study
by: Robert Avram, et al.
Published: (2023)

The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention
by: Zhaowei Zhang, et al.
Published: (2020)

Efficacy and safety of nicorandil on perioperative myocardial injury in patients undergoing elective percutaneous coronary intervention: results of the PENMIPCI trial
by: Ye Z, et al.
Published: (2018)

HOMOCYSTEINE-LOWERING THERAPY AND LONG-TERM PROGNOSIS AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
by: O. O. Shakhmatova, et al.
Published: (2016)

Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
by: A. V. Panov
Published: (2021)

Impact of Frailty on the First 30 Days of Major Cardiac Events in Elderly Patients with Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention
by: Rachmat Hamonangan, et al.
Published: (2016)

Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI)
by: Renan Sukmawan, et al.
Published: (2021)

Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention
by: Kreutz RP, et al.
Published: (2016)

Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention
by: Patel V, et al.
Published: (2014)

Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis
by: Fan ZG, et al.
Published: (2019)

Frequency and Prognostic Value of Acute Periprocedural Myocardial Injury in Elective Percutaneous Coronary Interventions
by: E. O. Nalesnik, et al.
Published: (2024)

HIGH VERSUS STANDARD CLOPIDOGREL MAINTENANCE DOSE AFTER PERCUTANEOUS CORONARY INTERVENTION AND EFFECTS ON PLATELET INHIBITION, ENDOTHELIAL FUNCTION, AND INFLAMMATION. RESULTS OF THE ARMYDA-150 MG (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED STUDY
by: G. Patti, et al.
Published: (2016)

Sensitivity to clopidogrel and outcomes of long-term dual antiplatelet therapy in patients with multifocal atherosclerosis
by: M. B. Khakimova, et al.
Published: (2024)

Effect of pretreatment with omega-3 supplement on cardiac necrosis markers in chronic kidney disease patients undergoing elective percutaneous coronary intervention
by: Farzaneh Foroughinia, et al.
Published: (2017)